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Background: The different effects of LDL-C levels and statins therapy on coronary atherosclerotic plaque between
Western and Asian remain to be settled.
Methods: PubMed, EMBASE, and Cochrane databases were searched from Jan. 2000 to Sep. 2014 for randomized
controlled or blinded end-points trials assessing the effects of LDL-C lowering therapy on regression of coronary
atherosclerotic plaque (CAP) in patients with coronary heart disease by intravascular ultrasound. The significance of
plaques regression was assessed by computing standardized mean difference (SMD) of the volume of CAP between
the baseline and follow-up.
Results: Twenty trials (ten in the West and ten in Asia) were identified. For Westerns, Mean lowering LDL-C by
49.4% and/or to level 61.9 mg/dL in the group of patients with baseline mean LDL-C 123.2 mg/dL could significantly
reduce the volume of CAP at follow up (SMD −0.156 mm3, 95% CI −0.248 ~ −0.064, p = 0.001). LDL-C lowering by
rosuvastatin (mean 40 mg daily) could significantly decrease the volumes of CAP at follow up. For Asians, Mean lowering
LDL-C by 36.1% and/or to level 84.0 mg/dL with baseline mean LDL-C 134.2 mg/dL could significantly reduce the
volume of CAP at follow up (SMD −0.211 mm3, 95% CI −0.331 ~ −0.092, p = 0.001). LDL-C lowering by rosuvastatin
(mean 14.1 mg daily) and atorvastatin (mean 18.9 mg daily) could significantly decrease the volumes of CAP at follow up.
Conclusions: There was a different effect of LDL-C lowering on CAP between Westerns and Asians. For regressing CAP,
Asians need lower dosage of statins or lower intensity LDL-C lowering therapy than Westerns.
Keywords: Low-density lipoprotein-cholesterol, Coronary atherosclerotic plaque, Intravascular ultrasound, Coronary artery
disease, Western, AsianBackground
Atherosclerotic plaque is the hallmark and cornerstone of
atherosclerotic disease. Disruption of coronary atheroscler-
otic plaque (CAP) may lead to sudden cardiac death, acute
myocardial infarction, or unstable angina [1]. Intravascular
ultrasound (IVUS) is considered to be gold standard for
measurement of atherosclerotic plaque [2].
The meta-analysis of twenty trials evaluated the effects
of LDL-C lowering on CAP indicated that intensive
LDL-C lowering with statins could slow atherosclerotic
plaque progression and lead to plaque regression [3].* Correspondence: fqz301@yahoo.com; cyundai@medmail.com.cn
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unless otherwise stated.But the meta-analysis did not investigate the effects of
LDL-C lowering on CAP in different race.
In this meta-analysis, we investigated the difference
between Western and Asian in the effect of LDL-C
lowering therapy on the progression of the CAP from
the current trials on LDL-C lowering therapy retarding
the progression of the CAP and identified the different
targets of LDL-C that result in the regression of the CAP
for Western and Asian.Methods
Materials and methods of this meta-analysis were detailed
in the paper by Gao et al. [3].is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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An electronic literature search was performed to identify
all relevant studies published in PubMed, EMBASE, and
Cochrane databases in the English language from Jan. 1,
2000 to Sep. 13, 2014, using the terms “atherosclerosis”
and “cholesterol blood level”. Trials were included using
the criteria as: 1) randomized controlled or prospective,
blinded end-points trials, and its primary end point was
CAP change detected by IVUS; 2) report of LDL-C levels at
baseline and follow-up; 3) data on the volume of CAP at
baseline and follow-up, and volume of CAP was calculated
as vessel volume minus lumen volume; Exclusion criteria
were: 1) only CAP area or volume index or percent
atheroma volume were detected; 2) the levels of LDL-C at
baseline or follow-up were not provided; and 3) target
plaques were unstable.
Data extraction and quality assessment
Two investigators independently reviewed all potentially
eligible studies and collected data on patient and
study characteristics, and any disagreement was re-
solved by consensus. The primary end point of this
study was the volume change of CAP detected by
IVUS. Quality assessments of trials were evaluated
with Jadad quality scale.
Data synthesis and analysis
Volume changes of CAP from baseline to follow-up were
analyzed using standardized mean differences (SMD).
Volume changes of plaque in every arm were used
for pooled analysis. The trials were firstly grouped
into group Western and Asian according to the loca-
tion of the trials. Then, according to the levels and
the reducing percentage of LDL-C at follow-up, the
arms were grouped to following groups: ≤70, >70 ≤
100 HP, >70 ≤ 100 MP, >70 ≤ 100 LP, >100 mg/dL;
and <0, ≥0 < 30, ≥30 < 40, ≥40 < 50, ≥50% respectively
[3], to investigate the effect of different levels of
LDL-C at follow up on CAPs. According to statins,
the arms were grouped to: rosuvastatin, atorvastatin,
pitavastatin, simvastatin, fluvastatin and pravastatin
groups, to investigate the effect of different statins on
CAPs. The volume of CAP at follow up was compared
with that at baseline to evaluate effect of LDL-C levels on
regression of CAP.
Heterogeneity across trials (arms) was assessed via a
standard χ2 test with significance being set at p < 0.10
and also assessed by means of I2 statistic with significance
being set at I2 > 50%. Pooled analyses were calculated
using fixed-effect models, whereas random-effect models
were applied in case of significant heterogeneity across
trials (arms). Sensitivity analyses (exclusion of one study at
one time) were performed to determine the stability of
the results. Publication bias was assessed using theEgger regression asymmetry test. Statistical analyses were
performed using STATA software 12.0 (StataCorp, College
Station, Texas).
All continuous variables were expressed as mean ± SD,
and continuous variables were compared between the
Western and Asian groups using Student’s t test




The flow of selecting studies for the meta-analysis was
shown in Figure 1. Briefly, of the initial 673 articles, one
hundred and twenty-two of abstracts were reviewed,
resulting in exclusion of 102 articles, and 20 articles
were reviewed in full text, resulting in exclusion of 10
trials and inclusion of 18 additional trials cited in the
20 articles. Twenty two RCTs [4-25] and six blinded
end-points trial [26-31] were carefully evaluated, and
eight trials [4,8,9,18,19,21,27,31] were excluded be-
cause of specific the index of plaque or lack of some
data. Sixteen RCT (ESTABLISH [11], REVERSAL [10],
A-PLUS [5], ACTIVATE [6], ILLUSTRATE [7],
JAPAN-ACS [20], REACH [14], SATURN [16], ARTMAP
[17], ERASE [23], STRADIVARIUS [24], PERISCOPE
[25], and trials by Yokoyama M [12], by Kawasaki M [13],
by Hong MK [15], and Tani S [22]) and four blinded
end-points trial (ASTEROID [26], COSMOS [29], trial
by Jensen LO [28] and trial by Nasu K [30]) were finally
analyzed.
The characteristics of the included trials were as
same as in the study [3] and shown in Table 1.
Briefly, among the 20 trials, 10 trials are completed in
European, America and Australia [10,5-7,16,23-26,28], 10
in Asia [20,11-15,17,22,29,30], and there were 15 trials
assessing statins (statin vs. usual care in 6 trials
[11-14,22,30]; intensive statin vs. moderate statin treat-
ment in 5 trials [10,15-17,20]; follow up vs baseline in 3
trial [26,28,29], before acute coronary syndrome (ACS) vs
after ACS in one trial [23]), 2 trials assessing enzyme
acyl–coenzyme A: cholesterol acyltransferase (ACAT)
inhibition [5,6], one trial assessing cholesteryl ester
transfer protein (CETP) inhibitor torcetrapib [7], one
trial assessing a decreasing obesity drug: rimonabant
[24], and one trial assessing glucose-lowering agents
[25]. Overall, 5910 patients with coronary heart dis-
ease (CHD) underwent serial IVUS examination for
evaluating regression of CAP. Follow-up periods
ranged from 2 to 24 months. The levels of LDL-C of
each arm at baseline and follow-up were shown in
Table 2.
Risk of bias of included studies, evaluated through
Cochrane’s methods, showed an overall acceptable quality
of selected trials (Figures 2 and 3).
Figure 1 Flow diagram of study-screening process.
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http://www.biomedcentral.com/1471-2261/15/6The effect of the levels of LDL-C at follow-up on regression
of coronary atherosclerotic plaque in Western and Asian
For Western, meta-analysis indicated that LDL-C lowering
in group ≤70 mg/dL could lead to regression of CAP,
but LDL-C lowering in group >70 ≤ 100 HP, >70 ≤ 100
MP, >70 ≤ 100 LP and >100 mg/dL could not (Figure 4,
Table 3).
In group ≤70 mg/dL (including three arms) with mean
23.1 months of follow up, the volumes of CAP (160.6 mm3)
at follow up were significantly decreased, compared with
the volumes (171.4 mm3) at baseline [SMD −0.156 mm3,
95% CI (confidence interval) -0.248 ~ −0.064, p= 0.001].
There was no significant heterogeneity among arms (χ2 for
heterogeneity = 0.33, p =0.886, I2 = 0%).
Sensitivity analyses suggested that LDL-C lowering in
group ≤70 mg/dL could lead to regression of CAP with
reduction of the CAP volume ranged from −0.139 mm3
(SMD, 95% CI: −0.257 ~ −0.021) when the arm of 2006
ASTEROID Ros was omitted to −0.175 mm3 (SMD,95% CI: −0.317 ~ −0.034) when the arm of 2011
SATURN Ros was omitted. No publication bias was
found, the values of p by Egger’s test was 0.789.
For Asian, according to the levels of LDL-C at follow-up,
the arms were grouped to three groups: ≤70, >70 ≤ 100 HP
and >100 mg/dL.
LDL-C lowering in group ≤70 mg/dL and >70 ≤ 100 HP
could lead to regression of CAP, but LDL-C lowering in
group >100 mg/dL could not (Figure 5, Table 3).
In group ≤70 mg/dL (including four arms) with mean
6.9 months of follow up and group >70 ≤ 100HP mg/dL
(including eight arms) with mean 11.0 months of follow
up, the volumes of CAP (179.9, 87.5 mm3 respectively)
at follow up were significantly decreased, compared
with the volumes (192.2, 96.4 mm3 respectively) at base-
line [SMD −0.157 mm3, 95% CI −0.307 ~ −0.008, p =
0.039; SMD −0.211 mm3, 95% CI −0.331 ~ −0.092, p =
0.001; respectively]. There was no significant heterogen-
eity among arms (χ2 for heterogeneity = 0.24, p =0.955,
Table 1 Features of participating trials
Authors and
trial name




















2004 24/24 ACS 70/119 −44/-0.004 Ato 20 vs Diet 6 Plaque volume was sigificantly











on changes in plaque
by IVUS
2004 253/249 CAD 79/110 −46/-25 Ato 80 vs Pra40 18 Ato reduced progression of
coronary plaque compared
with Pra. Compared with
baseline values, Ato had no
change in atheroma burden,
whereas patients treated with


















7.8/9.1/10.9/1.7 Ava50, 250, and
750 vs Placebo
on the basis
of LDL-C < 125
18 Avasimibe did not favorably
alter coronary atherosclerosis
as assessed by IVUS.










2004 40 CAD 85 −46.3 Sim 40 15 Lipid-lowering therapy with
Sim is associated with a
significant plaque regression
in coronary arteries.







87/124 −35/-0.075 Ato 10 vs Diet 6 Treatment with Ato may
reduce volumes of
coronary plaques.
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6 Treatment with Ato and Pra
may not significantly reduce
volumes of coronary plaques.
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on changes in plaque
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2006 206/202 CAD 91/86 −9.6/-14.9 Pac100 vs
Placebo
18 Pac is not an effective strategy
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North America or Europe
Effects of CETP inhibitor on
changes in plaque by IVUS
2007 446/464 CAD 87/70 6.6/-13.3 Ato10-80 vs




24 The Tor was associated
with a substantial increase
in HDL-C and decrease in
LDL –C, and there was no
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diabete and CAD




18 In patients with type 2 diabetes
and CAD, treatment with Pio
resulted in a significantly lower
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on regression of coronary





87.6/86.3 −4.7/-3.6 Rim 20 mg vs
Placebo on bases
of statins therapy
18 Rim can reduce progression









Effects of statins on
changes in plaque
by IVUS
2009 127/125 ACS 84/81 −36/-36 Ato 20 vs Pit 4 10 The administration of Pit or









Evaluate the effect of
rosuvastatin on plaque
volume in patients





83 −38.6 Ros <20 14 Ros exerted significant
regression of coronary
plaque volume in Japanese
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2009 38/36 ACS 77/63 8.5/-37 Before ACS vs
After ACS
<2 Newly initiated statin therapy
is associated with rapid
regression of coronary
atherosclerosis.




but blinded end. Japan
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2009 40/39 stable
angina
98.1/121 −32.3/-1.1 Flu 60 vs Con 12 One-year lipid-lowering




















Table 1 Features of participating trials (Continued)








78/64 −34.5/-44.8 Sim 20 vs Ros 10 12 Statin treatments might
be associated with significant








Compare the effect of
these two intensive statin
regimens on the progression
of coronary atherosclerosis.
2011 519/520 CHD 70.2/62.6 −41.5/-47.8 Ato 80 vs Ros 40 24 Maximal doses of Ros and
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atorvastatin 20 mg/day
versus rosuvastatin










Abbreviations: T Treatment, C Control, RCT randomized controlled trials, IVUS Intravascular ultrasound, CAD Coronary artery disease, ACS Acute coronary syndrome, CHD Coronary heart disease, Ato Atorvastatin,
Ros Rosuvastatin, Pra Pravastatin, Pit Pitavastatin, Sim Simvastatin, Flu Fluvastatin, Con Control, Pac Pactimibe, Tor Torcetrapib, Ava 50, 250, 750, Avasimibe 50, 250, 750 mg, T/C Treat/Control, Gli Glimepiride,


















Table 2 The levels of LDL-C at baseline and follow up in each arm of included trials
Authors Trial name Management
in each arm
N LDL-C level
At baseline At follow-up
Tardif JC A-PLUS Avasimibe50 108 92.8 ± 1.7 100*
Tardif JC A-PLUS Avasimibe250 98 93.4 ± 1.6 101.9*
Tardif JC A-PLUS Avasimibe750 117 91.4 ± 1.6 101.4*
Tardif JC A-PLUS Placebo 109 89.6 ± 1.6 91.1*
Okazaki S ESTABLISH Control 24 123.9 ± 35.3 119.4 ± 24.6
Okazaki S ESTABLISH Atorvastatin 24 124.6 ± 34.5 70.0 ± 25.0
Yokoyama M Control 30 131.5 ± 23# 124.5 ± 24.1#
Yokoyama M Atorvastatin 29 133 ± 13 87 ± 29
Nissen SE REVERSAL Atorvastatin 253 150.2 ± 27.9 78.9 ± 30.2
Nissen SE REVERSAL Pravastatin 249 150.2 ± 25.9 110.4 ± 25.8
Nissen SE ACTIVATE Pactimibe 206 101.4 ± 27.7 91.3
Nissen SE ACTIVATE Placebo 202 101.5 ± 31.1 86.4
Nissen SE ILLUSTRATE Atorvastatin 446 84.3 ± 18.9 87.2 ± 22.6
Nissen SE ILLUSTRATE Atorva + torcetrapib 464 83.1 ± 19.7 70.1 ± 25.4
Kawasaki M Control 17 152 ± 20 149 ± 24
Kawasaki M Pravastatin 18 149 ± 19 102 ± 13
Kawasaki M Atorvastatin 17 155 ± 22 95 ± 15
Hiro T JAPAN-ACS Pitavastatin 125 130.9 ± 33.3 81.1 ± 23.4
Hiro T JAPAN-ACS Atorvastatin 127 133.8 ± 31.4 84.1 ± 27.4
Nissen SE ASTEROID Rosuvastatin 349 130.4 ± 34.3 60.8 ± 20.0
Takayama T COSMOS Rosuvastatin 126 140.2 ± 31.5 82.9 ± 18.7
Lee CW ARTMAP Atorvastatin 143 110 ± 31 56 ± 18
Lee CW ARTMAP Rosuvastatin 128 109 ± 31 53 ± 18
Yamada T REACH Atorvastatin 26 123 ± 17 83 ± 22
Yamada T REACH Control 32 115 ± 14 115 ± 30
Nasu K Fluvastatin 40 144.9 ± 31.5 98.1 ± 12.7
Nasu K Control 39 122.3 ± 18.9 121.0 ± 21.2
Nicholls SJ SATURN Atorvastatin 519 119.9 ± 28.9 70.2 ± 1.0
Nicholls SJ SATURN Rosuvastatin 520 120.0 ± 27.3 62.6 ± 1.0
Hong MK Simvastatin 50 119 ± 30 78 ± 20
Hong MK Rosuvastatin 50 116 ± 28 64 ± 21
Tani S Pravastatin 52 130 ± 38 104 ± 20
Tani S Control 23 123 ± 28 120 ± 30
Rodés-C Bef ERASE Statins before ACS 38 71 ± 23 77 ± 25
Rodés-C Aft ERASE Statins after ACS 36 100 ± 30 63 ± 17
Jensen LO Simvastatin 40 158.7 ± 30.6 85.1 ± 22.1
Nissen SE PERISCOPE Statins + Gli 181 94.4 ± 32.9 96.1 ± 30.4
Nissen SE PERISCOPE Statins + Pio 179 93.5 ± 30.7 95.6 ± 28.9
Nissen SE STRADIVARIUS Statins + Rim 335 91.9 ± 27.9 87.6 ± 30.5
Nissen SE STRADIVARIUS Statins + Con 341 89.5 ± 32.2 86.3 ± 30.3
Note: *calculated on the bases of baseline levels and change percentage at follow up5.
#calculated according to Figure 2 in the paper12.
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Figure 2 Methodological quality summary of each included trial.
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http://www.biomedcentral.com/1471-2261/15/6I2 = 0% for group ≤70 mg/dL; χ2 for heterogeneity =
2.68, p =0.913, I2 = 0% for group >70 ≤ 100HP mg/dL).
Sensitivity analyses suggested that LDL-C lowering
in group >70 ≤ 100 HP mg/dL could lead to regression
of CAP with reduction of the CAP volume ranged
from −0.177 mm3 (SMD, 95% CI: −0.314 ~ −0.040)
when the arm of 2009 JAPAN-ACS Ato was omitted
to −0.231 mm3 (SMD, 95% CI: −0.368 ~ −0.094) when
the arm of 2009 COSMOS Ros was omitted; but that
LDL-C lowering in group ≤ 70 mg/dL could not signifi-
cantly lead to regression of CAP with reduction of the
CAP volume when the arm of 2012 ARTMAP Ros or
2012 ARTMAP Ato was omitted (Table 3).
No publication bias was found, the values of p by
Egger’s test for group ≤70 and >70 ≤ 100HP mg/dL were
0.970, 0.083 respectively.
The effect of the LDL-C reducing percentage at follow-up
on regression of CAP in Western and Asian
For Western, meta-analysis showed that LDL-C lowering
in group ≥40 < 50, ≥50% could lead to regression of CAP,
but LDL-C lowering in group <0, ≥0 < 30% and ≥30 < 40
could not (Figure 6, Table 3).Figure 3 Methodological quality graph: each methodological qualityIn group ≥40 < 50% (including four arms) with mean
22.6 months of follow up, the volumes of CAP
(143.1 mm3) at follow up were significantly decreased,
compared with the volumes (148.8 mm3) at baseline
(SMD −0.095 mm3, 95% CI −0.171 ~ −0.019, p = 0.014).
There was no significant heterogeneity among arms (χ2
for heterogeneity = 1.64, P = 0.651, I2 = 0%).
Sensitivity analyses showed that LDL-C lowering in
group ≥40 < 50 could still lead to regression of CAP
with reduction of the plaque volume ranged
from −0.065 mm3 (95% CI −0.163 ~ 0.032) when the
arm of 2011 SATURN Ros was omitted to −0.116 mm3
(SMD, 95% CI −0.201 ~ −0.032) when 2004 REVERSAL
Ato was omitted. Publication bias analysis suggested
the values of p by Egger’s test were 0.804.
In group group <0, ≥0 < 30% and ≥30 < 40, meta-
analysis were showed in Table 3.
For Asian, according to the reducing percentage of
LDL-C at follow-up, the arms were grouped to following
groups: ≥0 < 30, ≥30 < 40, ≥40 < 50.
LDL-C lowering in group ≥30 < 40, ≥40 < 50% could lead
to regression of CAP, but LDL-C lowering in group ≥0 <
30% could not (Figure 7, Table 3).item presented as percentages across all included studies.
Figure 4 Meta- analysis of the effects of reduction levels of LDL-C at follow up on the regression of coronary atherosclerotic plaque in
Western. Abbreviations: Ato, Atorvastatin; Ros, Rosuvastatin; Pra, Pravastatin; Pit, Pitavastatin; Sim, Simvastatin; Flu, Fluvastatin; Con, Control; Pac,
Pactimibe; Tor, Torcetrapib, Ava 50, 250, 750, Avasimibe 50, 250, 750 mg; Bef, before ACS; Aft, after ACS; Gli, Glimepiride; Pio, Pioglitazone;
Rim, Rimonabant.
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http://www.biomedcentral.com/1471-2261/15/6In group ≥30 < 40% (including nine arms) with mean
10.9 months of follow up, and group ≥40 < 50% (including
four arms) with mean 6.9 months of follow up, the volumes
of CAP (90.0, 179.9 mm3 respectively) at follow up were
significantly decreased, compared with the volumes (98.6,
192.2 mm3 respectively) at baseline (SMD −0.206 mm3,
95% CI −0.324 ~ −0.088, p = 0.001; SMD −0.157 mm3,
95% CI −0.307 ~ −0.008, p = 0.039; respectively). There
was no significant heterogeneity among arms (χ2 for
heterogeneity = 2.91, P = 0.840, I2 = 0%; χ2 for hetero-
geneity = 0.33, p =0.955, I2 = 0%; for group ≥30 < 40, and
group ≥40 < 50 respectively).
Sensitivity analyses showed that LDL-C lowering in
group ≥30 < 40% could still lead to regression of CAP with
reduction of the plaque volume ranged from −0.172 mm3
(95% CI −0.306 ~ −0.038) when the arm of 2009
JAPAN-ACS Ato was omitted to −0.223 mm3 (SMD,
95% CI −0.357 ~ −0.089) when 2009 COSMOS Ros was
omitted. Publication bias analysis suggested that bias
was significant with 0.004 of p value by Egger’s test.Mean levels of LDL-C at baseline and follow up, mean
reducing percentage of LDL-C in each group were
showed in Table 4.The effect of lowering LDL-C by statins on regression of
coronary atherosclerotic plaque in Western and Asian
For Western, atorvastatin, rosuvastatin, pravastatin
and simvastatin were used in trials to investigate the
effects of LDL-C lowering on CAP. Meta-analysis indi-
cated that LDL-C lowering by rosuvastatin could lead
to regression of CAP, but LDL-C lowering by atorva-
statin, pravastatin, and simvastatin could not (Figure 8,
Table 5).
LDL-C lowering by rosuvastatin (mean 40.0 mg daily
for mean 24 months) could significantly decrease the vol-
umes of CAP at follow up, compared with the volumes at
baseline (SMD −0.158 mm3, 95% CI: −0.253 ~ −0.064, p =
0.001). There was no significant heterogeneity among
arms (χ2 for heterogeneity = 0.18, p =0.672, I2 = 0%).













χ2 test (p) I2 Lower SMD (95% CI) Upper SMD (95% CI)
Western
<70 mg 3(905) 171.4 ± 32.7 160.6 ± 29.7 −0.156(−0.248 ~ −0.064, 0.001) 0.33(0.886) 0 −0.139 (−0.257 ~ −0.021)
Without 2006 ASTEROID Ros
−0.175 (−0.317 ~ −0.034)
Without 2011 SATURN Ros
0.789
>70≤ 100 HPmg 3(812) 151.9 ± 30.4 147.9 ± 31.9 −0.065(−0.136 ~ 0.032, 0.189) 0.71(0.699) 0 0.987
>70≤ 100 MPmg 5(1548) 195.8 ± 2.3 191.8 ± 4.7 −0.045(−0.115 ~ −0.026, 0.215) 1.59(0.811) 0 0.500
>70≤ 100 LPmg 6(1061) 201.2 ± 15.1 197.3 ± 15.0 −0.045(−0.130 ~ 0.040, 0.301) 1.14(0.950) 0 0.241
>100 mg 3(464) 197.6 ± 3.5 201.1 ± 1.9 0.034(−0.094 ~ 0.163, 0.601) 0.03(0.984) 0
>50% 1(349) 212.2 ± 81.3 197.5 ± 79.1 −0.183(−0.332 ~ −0.035, 0.016)
>40≤ 50% 4(1332) 148.8 ± 24.0 143.1 ± 25.6 −0.095(−0.171 ~ −0.019, 0.014) 1.64(0.651) 0 −0.065 (−0.163 ~ 0.032)
Without 2011 SATURN Ros
−0.116 (−0.201 ~ −0.032)
Without 2004 REVERSAL Ato
0.804
>30≤ 40% 1(36) 169.1 ± 77.3 161.5 ± 75.2 −0.099(−0.561 ~ 0.363, 0.675) 0.00(0.000) 0
>0≤ 30% 6(1797) 195.6 ± 2.1 192.9 ± 5.1 −0.032(−0.098 ~ 0.033, 0.335) 2.45(0.784) 0
<0% 8(1276) 201.2 ± 13.8 198.3 ± 13.8 −0.034(−0.111 ~ 0.044, 0.396) 1.55(0.981) 0 0.087
Asian
<70 mg 4(345) 192.2 ± 59.9 179.9 ± 53.0 −0.157(−0.307 ~ −0.008, 0.039) 0.24(0.955) 0 −0.126 (−0.314 ~ 0.063)
Without 2012 ARTMAP Ros
−0.187 (−0.383 ~ 0.008)
Without 2012 ARTMAP Ato
0.970
>70≤ 100 HPmg 8(540) 96.4 ± 99.3 87.5 ± 92.0 −0.211(−0.331 ~ −0.092, 0.001) 2.68(0.913) 0 −0.177 (−0.314 ~ −0.040)
Without 2009 JAPAN-ACS Ato
−0.231(−0.368 ~ −0.094)
Without 2009 COSMOS Ros
0.083
>100 mg 8(235) 133.0 ± 139.6 134.3 ± 143.8 −0.029(−0.210 ~ 0.152, 0.750) 2.14(0.952) 0
>40≤ 50% 4(345) 192.2 ± 56.9 179.9 ± 53.0 −0.157(−0.307 ~ −0.008, 0.039) 0.33(0.955) 0 −0.126 (−0.314 ~ 0.063)
Without 2012 ARTMAP Ros
−0.187 (−0.383 ~ 0.008)
Without 2012 ARTMAP Ato
0.970
>30≤ 40% 9(558) 98.6 ± 98.5 90.0 ± 91.6 −0.206(−0.324 ~ −0.088, 0.001) 2.91(0.840) 0 −0.172 (−0.306 ~ −0.038)
Without 2009 JAPAN-ACS Ato
−0.223 (−0.357 ~ −0.089)
Without 2009 COSMOS Ros
0.004


















Figure 5 Meta- analysis of the effects of reduction levels of LDL-C at follow up on the regression of coronary atherosclerotic plaque in
Asian. Abbreviation as in Figure 4.
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http://www.biomedcentral.com/1471-2261/15/6Sensitivity analyses suggested that lowering LDL-C by
rosuvastatin could lead to regression of CAP with reduc-
tion of the plaque volume ranged from −0.142 mm3
(SMD, 95% CI: −0.263 ~ −0.020) when the arm of 2006
ASTEROID Ros was omitted to −0.183 mm3 (SMD, 95%
CI: −0.332 ~ −0.035) when the arm of 2011 SATURN
Ros was omitted. But publication bias was found, the
values of p by Egger’s test was 0.000 (Table 5).
For Asian, atorvastatin, rosuvastatin, pitavastatin,
pravastatin, fluvastatin and simvastatin were used in tri-
als to investigate the effects of LDL-C lowering on CAP.
Meta-analysis indicated that LDL-C lowering by rosu-
vastatin, atorvastatin could lead to regression of CAP,
but LDL-C lowering by pitavastatin, pravastatin, fluvas-
tatin and simvastatin could not (Figure 9, Table 5).
LDL-C lowering by rosuvastatin (mean 14.1 mg daily for
mean 10.3 months), atorvastatin (mean 18.9 mg daily for
mean 7.8 months) could significantly decrease the vol-
umes of CAP at follow up, compared with the volumes at
baseline (SMD −0.172 mm3, 95% CI: −0.331 ~ −0.012, p =
0.035; SMD −0.185, 95% CI: −0.330 ~ −0.040, p = 0.013;
respectively). There was no significant heterogeneity
among arms (χ2 for heterogeneity = 0.17, p =0.917, I2 = 0%for rosuvastatin; χ2 for heterogeneity = 1.94, p =0.858,
I2 = 0% for atorvastatin).
Sensitivity analyses suggested that lowering LDL-C by
rosuvastatin could not significantly lead to regression of
CAP when the arm of 2012 ARTMAP Ros or 2009
COSMOS Ros was omitted. Also, Lowering LDL-C by
atorvastatin could not significantly lead to regression of
CAP when the arm of 2009 JAPAN-ACS Ato was omit-
ted. No publication bias was found, the values of p by
Egger’s test for rosuvastatin and atorvastatin group were
0.660, 0.456 respectively (Table 5).
Intensity of lowering LDL-C by different statins was
shown in Table 6. Rosuvastatin and atorvastatin could
reduce LDL-C by more than 40%.
The difference between Western and Asian in usage
of statins
The meta analysis showed that rosuvastatin and atorva-
statin can regress CAP (Table 5). LDL-C levels, intensity
of lowering LDL-C by rosuvastatin and atorvastatin, its
dosage and duration were compared between Western
and Asian (Table 7). Intensity of lowering LDL-C by
rosuvastatin and atorvastatin in Western group were
Figure 6 Meta- analysis of the effects of reduction percentages of LDL-C at follow up on the regression of coronary atherosclerotic
plaque in Western. Abbreviation as in Figure 4.
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vastatin and atorvastatin in Asian group were signifi-
cantly lower than those in Western group, and the
duration of statins administration in Asian group were
significantly shorter than those in Western, as showed in
Table 7.
Discussion
This meta-analysis revealed that intensive LDL-C lower-
ing can regress CAP both in Western and Asian. For
regressing CAP, the dosage of statins administrated in
Westerns was different from that in Asians. Asians need
lower dosage of atorvastatin or rosuvastatin than Westerns
though there was no difference between Westerns and
Asians in pharmacokinetic and pharmacodynamic study
[32,33].
The effect difference of LDL-C lowering on CAP between
Western and Asian
For Western including American, Canadian, German,
French, English, Australian and Dane [10,5-7,16,23-26,28],
the meta-analysis (Table 3) in subgroup ≤70 mg
and ≥40 < 50% of Western indicated that LDL-C levellowering to <69.3 mg or reducing by > 45% for
22.6 months of follow up (Table 4) could lead to re-
gression of CAP, but the meta-analysis (Table 3) in
subgroup >70 ≤ 100 HP mg of Western showed that
LDL-C level lowering to 73.2 mg or reducing by 43.6%
for 21.7 months of follow up (Table 4) was not enough
for regressing CAP.
For Asian including Japanese and Korean [20,11-15,
17,22,29,30], the meta-analysis in subgroup ≤70 mg
and ≥40 < 50% of Asian indicated that LDL-C level
lowering to 57.0 mg or reducing by 47.2% for
6.9 months of follow up could lead to regression of
CAP, but sensitivity analyses showed that LDL-C lowe-
ring in this two subgroup could not significantly lead
to regression of CAP when the arm of 2012 ARTMAP
Ros or 2012 ARTMAP Ato was omitted (Table 3). The
meta-analysis in subgroup ≥ 30 < 40% of Asian indi-
cated that LDL-C level lowering to 84.6 mg or reducing
by 36.0% for 10.9 months of follow up could also lead
to regression of CAP, but publication bias was signifi-
cant. The meta-analysis in subgroup >70 ≤ 100HP mg
of Asian with good sensitivity and no publication bias in-
dicated that LDL-C level lowering to 84.0 mg or reducing
Figure 7 Meta- analysis of the effects of reduction percentages of LDL-C at follow up on the regression of coronary atherosclerotic
plaque in Asian. Abbreviation as in Figure 4.
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gression of CAP (Table 3).
Taken all the results of meta-analysis together, for
Western, it was recommended that LDL-C level might
be reduced by >45% or to a target level < 69 mg/dL for
regressing CAP; for Asian, LDL-C level might be re-
duced by >36% or to a target level < 84 mg/dL.Different effects of statins on Westerns and Asians
Whether statins has different effect on Westerns and
Asians remains to be settled.
The study by Lee E et al. [34] and MEGA Study [35]
suggested statins have different effects on Westerns
and Asians. In 2005, Lee E et al. [34] prospectively ex-
amined the pharmacokinetics of rosuvastatin in White
and Asian individuals living in Singapore, and reported
that plasma exposure to rosuvastatin and its metabo-
lites was significantly higher in Chinese, Malay, and
Asian-Indian subjects compared with Western subjects
living in the same environment. But the mechanisms
underlying ethnic differences in rosuvastatin dispos-
ition remain to be unearthed [36]. MEGA Study [35]indicated that a small dose of pravastatin that was half
the dose administered to western patients, reduced
LDL-C by 19-22% (which is lower than that reductions
of 23–35% in western patients), but could substantially
reduce the risk of coronary heart disease in Japanese.
But two meta-analysis did not demonstrate the dif-
ference of rosuvastatin and atorvastatin on Westerns
and Asians. The meta-analysis including the 36 trials
of pharmacodynamics of rosuvastatin in Western and
Asian hypercholesterolemia patients did not confirm
that there was significant difference in the exposure-
response relationship for LDL-C reduction between
Westerners and Asians [33].The meta-analysis includ-
ing 22 pharmacokinetic studies also demonstrated no
differences in the systemic exposure to atorvastatin be-
tween Asian and Caucasian subjects [32].
Our meta-analysis revealed that there were differ-
ence of rosuvastatin and atorvastatin in lowering LDL-
C and regressing CAP between Westerns and Asians.
The meta-analysis of rosuvastatin including 2 trials
with 869 Western patients indicated that 40 mg of
rosuvastatin daily for 24 months with reducing LDL-C
by 49.9% could regress CAP. But the meta-analysis of
Table 4 Levels and reducing percentage of LDL-C and duration in each group in Western and Asian (Mean ± SD)










≤70 mg 905 123.2 ± 6.9 61.9 ± 0.9 49.4 ± 3.5 37 ~ 53 23.1 ± 4.3
>70≤ 100 HPmg 812 131.3 ± 15.2 73.6 ± 4.8 43.2 ± 2.2 41.5 ~ 46.7 21.7 ± 3.1
>70≤ 100 MPmg 1548 91.3 ± 6.9 82.4 ± 8.2 9.0 ± 4.5 3.6 ~ 14.9 19.8 ± 2.7
>70≤ 100 LPmg 1061 88.5 ± 5.5 91.5 ± 5.4 −4.7 ± 2.5 −1.7 ~ −8.5 19.9 ± 4.5
>100 mg 464 123.4 ± 28.9 106.3 ± 4.4 8.7 ± 17.5 −10.9 ~ 25.0 18.0 ± 0.0
>50% 349 130.4 ± 0.0 60.8 ± 0.0 53.4 ± 0.0 53.4 ~ 53.4 24.0 ± 0.0
>40≤ 50% 1332 126.9 ± 13.1 69.3 ± 6.5 45.0 ± 2.8 41.5 ~ 47.8 22.6 ± 2.7
>30≤ 40% 36 100.2 ± 30.2 63.1 ± 17.4 37.0 37 ~ 37 2.0 ± 0.0
>0≤ 30% 1797 99.4 ± 21.4 86.2 ± 12.2 11.2 ± 6.9 3.6 ~ 25.0 19.5 ± 2.6
<0% 1276 89.1 ± 5.3 93.2 ± 6.2 −5.6 ± 3.1 −1.7 ~ −10.9 19.6 ± 4.2
Asian
≤70 mg 345 111.5 ± 4.3 57.0 ± 5.0 47.2 ± 1.7 44 ~ 49 6.9 ± 2.1
>70≤ 100 HPmg 540 134.2 ± 7.8 84.0 ± 5.0 36.1 ± 1.8 32.3 ~ 39.0 11.0 ± 2.2
>100 mg 235 128.6 ± 10.5 117.2 ± 11.9 7.3 ± 10.7 0 ~ 32 7.8 ± 2.8
>40≤ 50% 345 111.5 ± 4.3 57.0 ± 5.0 47.2 ± 1.7 44 ~ 49 6.9 ± 2.1
>30≤ 40% 558 134.7 ± 8.1 84.6 ± 5.8 36.0 ± 1.9 32 ~ 39 10.9 ± 2.4
>0≤ 30% 217 126.9 ± 9.1 118.3 ± 11.5 5.3 ± 8.3 0 ~ 20.0 8.0 ± 2.8
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showed that 14.1 mg of rosuvastatin daily for
10.3 months with reducing LDL-C by 44.0% could also
regress CAP though the result of sensitivity analyses is
not as good as that in Western (Table 5). The meta-Figure 8 Meta- analysis of the effects of LDL-C lowering by different
Western. Abbreviation as in Figure 4.analysis of atorvastatin including 2 trials with 772
Western patients showed that 80 mg of atorvastatin
daily for 22 months with reducing LDL-C by 43.0%
could not significantly regress CAP. But the meta-
analysis of atorvastatin including 6 trials with 366statins on the regression of coronary atherosclerotic plaque in
Table 5 Results of meta-analysis in different statins groups in Western and Asian
Group Included arms
(and case)
Pooled SMD (95% CI, p) Heterogeneity test Sensitivity analyses Egger’s
testχ2 test (p) I2 Lower SMD (95% CI) Upper SMD (95% CI)
Western
Rosuvastatin 2(869) −0.158(−0.253 ~ −0.064, 0.001) 0.18(0.672) 0 −0.142 (−0.263 ~ −0.020)
Without 2006 ASTEROID Ros
−0.183 (−0.332 ~ −0.035)
Without 2011 SATURN Ros
0.000
Atorvastatin 2(772) −0.062(−0.162 ~ 0.038, 0.225) 0.62(0.432) 0 0.000
Pravastatin 1(249) 0.045(−0.131 ~ 0.221, 0.616)
Simvastatin 1(40) −0.133(−0.572 ~ 0.306, 0.552)
Asian
Rosuvastatin 3(304) −0.172(−0.331 ~ −0.012, 0.035) 0.17(0.917) 0 −0.143 (−0.352 ~ 0.066)
Without 2012 ARTMAP Ros
−0.189 (−0.397 ~ 0.019)
Without 2009 COSMOS Ros
0.660
Atorvastatin 6(366) −0.185(−0.330 ~ −0.040, 0.013) 1.94(0.858) 0 −0.113 (−0.292 ~ 0.068)
Without 2009 JAPAN-ACS Ato
−0.230 (−0.417 ~ −0.044)
Without 2012 ARTMAP Ato
0.456
Pravastatin 2(70) −0.197(−0.529 ~ 0.135, 0.245) 0.26(0.608) 0
Pitavastatin 1(125) −0.304(−0.553 ~ −0.055, 0.017)
Fluvastatin 1(40) −0.169(−0.608 ~ 0.270, 0.450)


















Figure 9 Meta- analysis of the effects of LDL-C lowering by different statins on the regression of coronary atherosclerotic plaque in
Asian. Abbreviation as in Figure 4.
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statin daily for 7.8 months with reducing LDL-C by
40.7% could significantly regress CAP though the re-
sult of sensitivity analyses is not as good as that ex-
pected (Table 5).Table 6 Levels and reducing percentage of LDL-C, dosage and
(Mean ± SD)





Rosuvastatin 869 57.8 ± 0.6 124.2 ± 5.1 61.9 ± 0.9
Atorvastatin 772 57.2 ± 1.0 129.8 ± 14.2 73.1 ± 4.1
Pravastatin 249 56.6 ± 0.0 150.2 ± 0.0 110.4 ± 0
Simvastatin 40 57.7 ± 0.0 158.7 ± 0.0 85.1 ± 0.0
Asian
Rosuvastatin 304 58.9 ± 3.3 123.1 ± 14.6 67.2 ± 13
Atorvastatin 366 60.9 ± 3.0 124.1 ± 12.7 72.9 ± 14
Pitavastatin 125 62.5 ± 11.5 130.9 ± 33.3 81.1 ± 23
Pravastatin 70 64.0 ± 1.8 134.9 ± 8.4 130.5 ± 0
Fluvastatin 40 63.0 ± 10.0 144.9 ± 31.5 98.1 ± 12
Simvastatin 50 58.0 ± 0.0 119.0 ± 0.0 78.0 ± 0.0Comparison between Western and Asian in using
rosuvastatin and atorvastatin indicated that the
dosages of rosuvastatin and atorvastatin in Asian
group were significantly lower than those in Western





Statin dosage (mg) Duration (month)
49.9 ± 2.6 40.0 ± 0.0 24.0 ± 0.0
43.0 ± 2.1 80.0 ± 0.0 22.0 ± 2.8
.0 25.0 ± 0.0 40.0 ± 0.0 18.0 ± 0.0
46.7 ± 0.0 40.0 ± 0.0 25.0 ± 0.0
.8 44.0 ± 4.8 14.1 ± 4.9 10.3 ± 3.7
.2 40.7 ± 5.5 18.9 ± 2.9 7.8 ± 2.2
.4 36.2 ± 19.5 4 8 ~ 12
.9 23.1 ± 5.3 16.3 ± 2.2 6.0 ± 0.0
.7 32.3 60 12
34.5 ± 0.0 20.0 ± 0.0 12.0 ± 0.0
Table 7 Comparison between Western and Asian in rosuvastatin and atorvastatin
Rosuvastatin Atorvastatin
Western Asian p Western Asian p
N/arm 869/2 304/3 772/2 366/6
Mean LDL-C at baseline (mg) 124.2 ± 5.1 123.1 ± 14.6 0.928 129.8 ± 14.2 124.1 ± 12.7 0.610
Mean LDL-C at follow up (mg) 61.9 ± 0.9 67.2 ± 13.8 0.642 73.1 ± 4.1 72.9 ± 14.2 0.986
LDL-C Mean reducing percentage 49.9 ± 2.6 44.0 ± 4.8 0.221 43.0 ± 2.1 40.7 ± 5.5 0.600
Statin dosage (mg) 40.0 ± 0.0 14.1 ± 4.9 0.006 80.0 ± 0.0 18.9 ± 2.9 <0.001
Duration (month) 24.0 ± 0.0 10.3 ± 3.7 0.016 22.0 ± 2.8 7.8 ± 2.2 <0.001
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in Westerns need atorvastatin 80 mg or rosuvastatin
40 mg, but in Asians need only atorvastatin 18.9 mg or
rosuvastatin 14.1 mg. For regressing CAP, 40 mg of
rosuvastatin might be daily administrated in Western for
24 months; 14.1 mg of rosuvastatin or 18.9 mg of ator-
vastatin might be daily administrated in Asian for 10.7
or 7.8 months respectively.
Study limitation
As with the meta-analysis [3], this study has some limi-
tations. There might be publication bias, difference of
the method detected and follow up duration. But those
differences in measurements and plaque selection did
not affect the change of the target plaque with LDL-C
levels. So, it has little effect on homogeneous of stud-
ies, and on the relationship between CAP change and
LDL-C level. But the trials of single statin on LDL-C
and CAP of specific population (for example, 2 trials
about atorvastatin on Western with 727 participants or
6 on Asian with 366 in Table 5) were limited, the effect
of statin on specific population remains to be investi-
gated. The duration of follow up between Western and
Asian was different (Table 4, 6 and 7), and treatment
duration might have some effect on CAP regression.
But the trials from Asian and Western were respect-
ively meta-analysed in this study. Therefore, the differ-
ence in follow-up duration between Asian and
Western did not influence the results of the meta-
analysis. The CAP regression in short period of statins
therapy in Asian suggested that the CAPs in Asian
were easily regressed by statins.
This meta-analysis did not investigate the effect of
reduction of LDL-C on adverse cardiovascular events
because all participants of the included trial must be
alive at follow up. But in the Extended-ESTABLISH
study, the incidence of adverse cardiovascular events
in statin group with CAP regression were reduced to
half that seen in the control group [37]. In the Ex-
tended JAPAN-ACS study [38], there was no signifi-
cantly different association of incidence of adversecardiovascular events with the CAP regression extent,
but that greater external elastic membrane volume re-
gression (<−6.56%) had a significantly lower incidence
of cumulative events than the lesser suggested the im-
portance of CAP regression in reducing adverse car-
diovascular events. A meta-analysis [39] included 7864
CAD patients showed that rates of plaque volume re-
gression were significantly associated with the inci-
dence of MI or revascularization.
Conclusions
LDL-C lowering therapy has a different effect on athero-
sclerotic plaque between Westerns and Asians. This sys-
temic review demonstrated that there is a different effect of
LDL-C lowering on CAP between Westerns and Asians.
For regressing CAP, Asians need lower dosage of statins or
lower intensity LDL-C lowering therapy (by >36%) than
Westerns (by 45%).
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